Related Experiment Video
Updated: Jun 29, 2025
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
Enhanced plant-derived vesicles for nucleotide delivery for cancer therapy
Sara Corvigno1, Yuan Liu1, Emine Bayraktar1,2
1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Abstract:
Small RNAs (microRNAs [miRNAs] or small interfering RNAs [siRNAs]) are effective tools for cancer therapy, but many of the existing carriers for their delivery are limited by low bioavailability, insufficient loading, impaired transport across biological barriers, and low delivery into the tumor microenvironment. Extracellular vesicle (EV)-based communication in mammalian and plant systems is important for many physiological and pathological processes, and EVs show promise as carriers for RNA interference molecules. However, some fundamental issues limit their use, such as insufficient cargo loading and low potential for scaling production. Plant-derived vesicles (PDVs) are membrane-coated vesicles released in the apoplastic fluid of plants that contain biomolecules that play a role in several biological mechanisms. Here, we developed an alternative approach to deliver miRNA for cancer therapy using PDVs. We isolated vesicles from watermelon and formulated a hybrid, exosomal, polymeric system in which PDVs were combined with a dendrimer bound to miRNA146 mimic. Third generation PAMAM was chosen due to its high branching structure and versatility for loading molecules of interest. We performed several in vivo experiments to demonstrate the therapeutic efficacy of our compound and explored in vitro biological mechanisms underlying the anti-tumor effects of miRNA146, which are mostly related to its anti-angiogenic activity.
Insights
Plant-derived vesicles (PDVs) offer a novel delivery system for microRNAs (miRNAs) in cancer therapy. This study demonstrates their potential to enhance anti-tumor effects by delivering miRNA146, primarily through anti-angiogenic mechanisms.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Therapeutics
Background:
- Small RNAs (miRNAs/siRNAs) show promise for cancer therapy but face delivery challenges like low bioavailability and poor tumor targeting.
- Extracellular vesicles (EVs) are explored as natural carriers for RNA interference molecules, yet face limitations in cargo loading and scalable production.
- Plant-derived vesicles (PDVs) are emerging as biocompatible carriers containing biomolecules relevant to biological mechanisms.
Purpose of the Study:
- To develop an alternative and effective delivery system for microRNA-based cancer therapy using plant-derived vesicles.
- To formulate a hybrid system combining PDVs with a dendrimer-bound miRNA mimic for enhanced delivery and efficacy.
- To investigate the in vivo therapeutic efficacy and in vitro anti-tumor mechanisms of the novel miRNA delivery system.
Main Methods:
- Isolation of vesicles from watermelon (plant-derived vesicles, PDVs).
- Formulation of a hybrid system using PDVs, a third-generation PAMAM dendrimer, and miRNA146 mimic.
- In vivo experiments to assess therapeutic efficacy against tumors.
- In vitro studies to elucidate the anti-tumor mechanisms, focusing on anti-angiogenic activity.
Main Results:
- Successful formulation of a hybrid PDV-dendrimer-miRNA146 system for targeted delivery.
- Demonstration of significant in vivo therapeutic efficacy of the developed compound.
- Identification of anti-angiogenic activity as a primary mechanism underlying the anti-tumor effects of miRNA146.
Conclusions:
- Plant-derived vesicles represent a promising and innovative platform for delivering therapeutic miRNAs in cancer treatment.
- The hybrid PDV-dendrimer system enhances miRNA delivery and exhibits potent anti-tumor effects, largely via anti-angiogenesis.
- This approach overcomes limitations of traditional carriers, offering a scalable and effective strategy for RNA-based cancer therapies.
More Related Videos
Related Concept Videos
00:59Gene Therapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...